Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Effect of Escitalopram vs. Reboxetine on Gastro-Intestinal Sensitivity of Patients With Major Depressive Disorder
This study is currently recruiting participants.
Study NCT00209807 Information provided by Hospital Universitari Vall d'Hebron Research Institute
First Received: September 13, 2005 Last Updated: April 28, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Major Depression
Pain
Abdominal Pain
Additional conditions recognized in this trial
Depression
Depressive Disorder
Depressive Disorder, Major
More general conditions related to this trial
Behavioral Symptoms
Mental Disorders
Mood Disorders
Signs and Symptoms
Signs and Symptoms, Digestive
Interventions listed in this trial
escitalopram
Reboxetine
No intervention
Additional drug interventions recognized in this trial
Citalopram
Dexetimide
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Uptake Inhibitors
Anti-Dyskinesia Agents
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antiparkinson Agents
Autonomic Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Parasympatholytics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Hospital Universitari Vall d'Hebron Research Institute
Back to top of Main Content
